

**CUMULATIVE INDEX**  
**VOLUME 21, NUMBERS 1-4, 1978**



Abortion

- in adolescent pregnancies, 1165–1166, 1175–1190
- anesthesia and analgesia in, 1181–1183
- and cervical size, 1181
- counseling with, 1179–1180
- demography of, 1175–1176
- first-trimester, 1185–1187
- laminaria tents in, 1185–1187
- legal problems in, 1181
- mortality rate in, 1176–1178
- postabortion instructions, 1188–1189
- preabortion procedures, 1183–1185
- and preservation of childbearing function, 1178–1179
- and Rh determination, 1181
- second-trimester, 1187–1189
- infections from, 461–462
- spontaneous
  - and  $\alpha$ -fetoprotein levels, 344
  - and  $\alpha$ -2-glycoprotein levels, 347
  - placental lactogen levels in, 365–366
- therapeutic, in cardiac disease, 433

Abruption placentae

- and fibrinogen degradation products in serum, 348
- ultrasonic diagnosis of, 323

Abscess, Bartholin's duct

- marsupialization in, 966, 975–977
- Word catheter in, 973, 977

Acetazolamide, in hypertension with pregnancy, 640

Acid-base homeostasis

- kidney responses in, 851–852
- maternal-fetal, 585–589

Acidosis, fetal

- primary, during hypoxia, 579–580
- secondary, 581

Acne, and androgen metabolism in skin, 121

Acromegaly, hyperprolactinemia in, 132

ACTH

- fetal production of, and premature labor, 534
- stimulation tests in childhood, 1143

Addison's disease, hyperprolactinemia in, 132

Adenosine triphosphate, and myometrial contractions, 141

Adolescence

- abortion in, 1165–1166, 1175–1190. *See also Abortion*
- adrenarche in, 109, 1143–1144
- endocrine changes in, 69–75, 1143–1144
- hypothalamic-pituitary function in, 1145–1146
- and initiation of puberty, 1146–1147
- menarche in, 72–73, 109, 1142–1143
- ovarian function in, 1144
- and physical changes of puberty, 1137–1140
- pregnancy in, 1135–1231
  - and adoption of infants, 1166
  - antecedents of, 1151–1159
  - complications of, 1191–1197
  - and contraceptive knowledge and use, 1155–1156, 1163, 1200, 1208–1212
  - and education for family life, 1154, 1200–1202
  - and failures of educational programs, 1154–1155
  - and family relationships, 1163–1164
  - four-year follow-up of, 1221–1222
  - and infant outcome, 1196
  - intervention programs for, 1168–1171
  - and Johns Hopkins program, 1231–1232
  - and lack of birth-control services, 1155–1156
  - long-range outcome of, 1215–1232
  - and need for early pregnancy detection, 1156
  - nutritional needs in, 1202–1208
  - and prognosis for mothers, 1166–1167

Adolescence, pregnancy in (*continued*)  
 psychological issues in, 1156–1158, 1162  
 reactions to, 1164–1165  
 seven-year follow-up of, 1222–1227  
 and sexual environment, 1153–1154  
 social factors in, 1152–1153  
 and Temple University program,  
     1170–1171  
 twelve-year follow-up of, 1227–1230  
 and YMED program in New York,  
     1168–1170  
 and secondary sexual development,  
     1140–1142  
 sexual behavior in, 1161–1162, 1199–1200  
     and counseling programs, 235–248  
 Adoption, maternal reactions to, in  
     adolescence, 1166  
 Adrenarche, 109, 1143–1144  
     precocious, 78  
 Adrenergic blocking agents, in hypertension  
     with pregnancy, 636–638  
 Age, maternal  
     and fetal chromosome abnormalities, 332  
     and outcome of pregnancy, 1217–1220  
 Alcohol  
     injections in pruritus of vulva, 1102  
     intravenous, in management of premature  
       labor, 535–537  
     maternal ingestion of, affecting newborn,  
       307  
 Alcoholism, and impotence, 230, 231  
 Aldosterone antagonists, in hypertension with  
     pregnancy, 640  
 Alkalosis, fetal, secondary, 581  
 Allergy, and contact dermatitis of vulva,  
     1002–1004  
 Alpha fetoprotein. *See*  $\alpha$ -Fetoprotein  
 Alphaprodine, in labor, 497  
 Amebiasis, smears in, 971  
 Amenorrhea  
     and hyperprolactinemia, 129–133  
     in polycystic ovarian disease, 99  
     primary, and delayed puberty, 81–84  
 Amiloride, in hypertension with pregnancy,  
     640  
 Amino acids  
     in amniotic fluid, 303  
     intraamniotic infusions of, 306–307  
     serum levels in pregnancy, 301  
       relation to infant growth, 305  
 Ammonium chloride therapy, in hypertension  
     with pregnancy, 640  
 Amniocentesis, 330  
     indications for, 336  
     preparation for, 336–337  
 Amniocentesis (*continued*)  
     technique of, 337–339  
     ultrasound with, 322–323, 337–338  
       bladder fullness affecting, 323, 338  
 Amniography, 330  
 Amniotic fluid  
     amino acid infusions in, 306–307  
     amino acid levels in, 303  
     analysis in hypertension with pregnancy,  
       631  
     antibacterial mechanisms in, 458–459  
     embolism of, and fibrinogen degradation  
       products in serum, 348  
     in fetal maturity evaluation, 550  
     lecithin/sphingomyelin ratio in, 553–555  
     in infants of diabetics, 450  
     and meconium aspiration syndrome, 605  
     proteins in, 301–302  
 AMP, cyclic, and action of peptide hormones,  
     55–57  
 Androgens  
     conversion to estrogens, 58, 110, 122  
     in corpus luteum, 48  
     in follicular fluid, 41  
     metabolism of, 115–122  
       clearance rates in, 118–120  
       in fetus and newborn, 120  
       in hirsute women, 121–122  
     production in normal females, 116–117  
     serum levels of  
       in childhood, 1144  
       in polycystic ovarian disease, 100–102  
     synthesis from cholesterol, 58  
 Androstenedione, production in normal  
     females, 116  
 Anemia, autoimmune hemolytic, in  
     pregnancy, 390  
 Anencephaly  
     and estriol levels in plasma, 360  
     ultrasound in prenatal diagnosis of, 315  
 Anesthesia, obstetric, 489–509  
     in abortion in teenagers, 1181–1183  
     in breech presentation, 525  
     caudal epidural, 501  
     in cesarean section, 504–508  
       general anesthesia, 507–508  
       local technique, 504–505  
       regional techniques, 505–507  
     inhalation anesthetics in, 504  
     in labor, 494–504  
     local anesthetics in, 498–504  
     lumbar epidural, 498–500  
     paracervical block in, 501–503  
     psychophysical methods, 495–496  
     pubendal block in, 503–504

Anesthesia (*continued*)  
 safety aspects in, 492–494  
 systemic medications in, 496–498

Angiography, renal, in pregnancy, 940

Angiomyolipoma, in pregnancy, 919

Angiotensin II, sensitivity to, and prediction of pregnancy-induced hypertension, 403

Anovulation, 87–95  
 bromocriptine in, 135, 160  
 in chromosomal or genetic defects, 88–90  
 in hypothalamic defects, 93–95  
 and induction of ovulation, 147–161  
 in ovarian defects, 88–91  
 in pituitary defects, 91–93  
 in polycystic ovarian disease, 99–112  
 pathophysiology of, 106–108

Antibiotics, prophylactic  
 in cesarean section, 472–473  
 in rheumatic heart disease, 432

Antibody tests, in pregnancy with urinary tract infections, 944

Anticoagulants, in pregnancy, affecting fetus, 433

Antihypertensive agents  
 affecting renin production, 645  
 contraindications to, 645  
 in preeclampsia-eclampsia, 892–893  
 in pregnancy, 635–645

Aortic coarctation, in pregnancy, 434–435

Apgar scores  
 breech presentation affecting, 523, 527  
 and fetal heart rate patterns, 574

Arachidonic acid, and premature labor, 535

Aromatase  
 activity in granulosa cells, 41  
 and estrogen synthesis, 58

Arthritis, rheumatoid, in pregnancy, 385–386, 900

Ascites, fetal, ultrasonic diagnosis of, 319–320

Asphyxia, fetal, in breech presentations, 520, 523

Aspiration, placental, 330

Aspirin, in management of premature labor, 539

Atrophic disorders, of vulva, 1032

Autoimmune disorders, in pregnancy, 385–393

Bacterial infections in pregnancy, 455–473  
 in abortions, 461–462  
 and antibacterial mechanisms in amniotic fluid, 458–459  
 and cervical protective barrier, 457  
 from Group B beta hemolytic streptococcus, 466–467

Bacterial infections (*continued*)  
 host defense mechanisms in, 455–459  
 in premature rupture of membranes, 462–466  
 and puerperal sepsis, 467–473  
 and transplacental passage of infectious agents, 459–460  
 urinary tract infections, 422–424

Bacteriuria, in pregnancy, 422–424, 870–871, 879, 921–926  
 in diabetics, 923  
 diagnosis of, 924–925, 943–944  
 management of, 925–926

Barbiturates, in labor, 496–497

Bartholine cyst and abscess  
 marsupialization in, 966, 975–977  
 Word catheter in, 973, 977

BCG vaccine. *See* Immunotherapy

Behcet syndrome, estrogen therapy in, 987

Bendroflumethiazide, in hypertension with pregnancy, 640

Benzthiazide, in hypertension with pregnancy, 640

Betadine, in vulvar lesions, 983–984

Bicarbonate, reabsorption in kidney, 851–852

Biopsy  
 renal, in pregnancy, 416–418  
 in vulvar diseases, 966

Birth control. *See* Contraceptives

Birth weight  
 and breech presentations, 516  
 maternal nutrition affecting, 306  
 and maternal weight gain, 305  
 in premature infants, 542

Bladder. *See also* Detrusor muscle  
 anatomy of, 824–825  
 cystometry of. *See* Cystometry  
 diseases with urinary incontinence, 734  
 dyssynergia of, 675, 677–678, 742–743  
 embryology of, 823–824  
 fullness of, affecting amniocentesis, 323, 338  
 hypotonic, 674–675  
 innervation of, 830  
 neck closure patterns in, 740–743  
 neural control of function, 653–667  
 neurogenic, 701, 743, 744  
 partial denervation for detrusor dyssynergia, 797–805  
 in pregnancy, 869, 908  
 pressure studies in incontinence, 690–691, 714  
 rotational descent of neck, 759, 761–762  
 rupture in pregnancy, 918  
 sensation of fullness in, 690  
 vesicoureteral junction anatomy, 863–865

## Blood

changes in preeclampsia-eclampsia, 885  
studies in vulvar disease, 968-969

## Blood pressure

in females, 620  
in pregnancy, 413, 431. *See also*  
Hypertension

## Blood vessels, in preeclampsia-eclampsia, 884

## Blood volume

hypovolemia in newborn, 601  
in pregnancy, 413-414, 431

## Boils, vulvar, 1001

Bowen's disease, compared to condyloma  
acuminatum, 1069-1070

## Bowman's capsule, 828

## Brain

estrogen receptors in, 22  
and neural control of urethrovesical  
function, 653-658  
in preeclampsia-eclampsia, 885

## Breast

cancer of, mammographic screening in, 1-13  
development in puberty, 1140-1142

## Breech presentation, 511-531

anesthesia in, 525  
cesarean section in, 516, 527-529  
and congenital abnormalities, 519-520  
diagnosis of, 513-514  
etiology of, 512-513  
fetal asphyxia in, 520, 523  
and growth retardation, 516-519  
and management of abnormalities, 515-516  
maneuvers in, 516  
morbidity from, 523-525  
mortality from, 521-523  
obstetric complications with, 520  
in prematurity, 512, 516, 525  
and selection of delivery method, 526-530  
vaginal delivery in, 527  
version in, 525-526

## Bromocriptine

and ovulation induction, 160  
and prolactin levels, 135, 160

## Bullous diseases of vulva, 1007-1021

## Bupivacaine, in labor, 498

## Burow's solution, in vulvar lesions, 983

## Calcium

intake in adolescent pregnancy, 1206  
and myometrial contractions, 140-141

## Calculi, urinary, in pregnancy, 420, 912-914,

927-928

## Calories

expenditure in pregnancy, 298  
in adolescence, 1205

Calories (*continued*)

supplementation in pregnancy, 306-307  
Candidiasis, of vulva, 998-999, 1033, 1035  
culture specimens in, 970  
gentian violet in, 973, 983  
scrapings of material in, 971  
smears in, 970

## Carbonic anhydrase inhibitors, in

hypertension with pregnancy, 640

## Carbuncles, of vulva, 1001

Carcinoma. *See* Tumors

## Cardiomyopathy, in pregnancy, 440

Cardiotachometer, in fetal heart rate  
monitoring, 564-565

Cardiovascular disease in pregnancy, 429-440  
cardiomyopathy, 440

coarctation of aorta, 434-435

Eisenmenger syndrome, 437

guidelines in management of, 431-434

Marfan's syndrome, 435-436, 900

mitral stenosis, 439-440

and prosthetic heart valves, 438-439

pulmonary hypertension, 437-438

surgery in, 433-434

tetralogy of Fallot, 436-437

## Catheterization

intrauterine, 569

urinary, in pregnancy, 895

Caustic therapy, in condyloma acuminatum,  
1070-1071

## Cellulitis, of vulva, 1001

Cephalopelvic disproportion, and breech  
presentation, 527

## Cesarean section

anesthesia in, 504-508

in breech presentation, 516, 527-529

in herpes simplex infection, 478

and incidence of infections, 467-473

prophylactic antibiotics in, 472-473

## Chancre, in syphilis, 2048-2049

## Chancroid, 1046-1047

clinical aspects of, 1046-1047

diagnosis of, 1047

intradermal test in, 971

smears in, 970, 971

treatment of, 1047

## Chemotherapy

in condyloma acuminatum, 1072

in melanoma, 1126

in vulvar diseases, 987-988

## Chickenpox, in pregnancy, 480-482

Childhood. *See also* Adolescence; Newborn

endocrine development in, 69, 1143

prolactin levels in, 128

## Chlamydia infections

**Chlamydia infections (continued)**

- and characteristics of organisms, 1043–1044
- serologic tests for, 969

**2-Chloroprocaine, in labor, 498**

**Chloroquine, in lichen sclerosus of vulva, 1104**

**Chlorothiazide, in hypertension with pregnancy, 640**

**Cholesterol, and steroidogenesis, 58**

**Chromosome studies, 331–336**

- abnormalities in, 332–336
- and anovulation, 88–90
- parents as carriers of, 333–334
- in Down's syndrome, 331, 333–334
- normal karyotypes in, 331, 332

**Clitoris**

- hood adhesions in, and sexual problems, 195
- and sexual responses, 184, 187, 193, 198

**Clomiphene, and ovulation induction, 149, 153–156, 159**

**Clonidine, in hypertension with pregnancy, 637**

**Coarctation of aorta, in pregnancy, 434–435**

**Coitus, painful. *See* Dyspareunia**

**Collagen diseases, in pregnancy, 899–901**

**Colposcystourethrography, 725–735**

**Condyloma**

- acuminatum, 1061–1076
  - antibody formation in, 1064
  - caustic therapy in, 1070–1071
  - chemotherapy in, 1072
  - clinical course of, 1067–1068
  - diagnosis of, 1069–1070
  - electrosurgery in, 977
  - etiology of, 1061–1062
  - 5-fluorouracil in, 988
  - giant, of Bushke and Lowenstein, 1066–1067
  - immunology of, 1062–1064
  - incidence of, 1064–1065
  - malignancy related to, 1065–1066
  - podophyllin in, 987, 1070–1071
  - surgery in, 1072
  - treatment of, 1070–1076
  - vaccine therapy in, 988, 1063–1064, 1072–1076
- latum, of vulva, 1033, 1036

**Congenital abnormalities**

- and breech presentations, 519–520
- and chromosome abnormalities, 322–336
- prenatal diagnosis of. *See* Prenatal diagnosis

**Contraceptive services, lack of, and adolescent pregnancies, 1155–1156**

**Contraceptives**

**Contraceptives (continued)**

- affecting sexual response, 197–198
- choice of, in young women, 246–248
- use in adolescence, 1163, 1200, 1208–1212

**Contractions, uterine, monitoring in labor, 569–571**

**Copper deficiency, in pregnancy, 308**

**Corpus luteum, 48–51**

**Corticosteroids**

- fetal production of, and premature labor, 534
- therapy with
  - affecting fetus, 388, 466
  - and lung maturation in infants, 466, 542, 557–558
- in pemphigus, 1010
- in vulvar diseases, 986–987, 1101

**Counseling, 163–277**

- and abortion in teenagers, 1179–1180
- active listening in, 168
- and attitude of acceptance, 169
- case reports of, 167, 170, 171
- for couples, 249–257
  - and analysis and management of problems, 251–255
  - community resources for, 257
  - and health promotion, 256
  - and prevention of problems, 256
- diagnostic process in, 167–170
- and doctor-patient relationships, 173–180
- embarrassment in, 172
- expressions of anger in, 171
- of formerly married, 259–266
  - and alleviation of guilt, 264–265
  - case reports of, 262, 263, 264, 265, 266
  - and changes in lifestyle, 265–266
  - goals in, 259–262
  - identification of needs in, 263–264
  - initial steps in, 262–263
  - loneliness in, 260
  - personal relationships in, 266
  - and relationships with friends, 260–261
  - sex roles in, 261–262
- initial request for, 166–167
- problems in, 170–172
- reactions in, 169–170
- reassurance in, 171
- in sexual problems, 191–202
  - and changing of attitudes and feelings, 199–200
- and communication between partners, 199

**and contraception prescription, 197–198**

**and diagnosis and treatment of pathology, 194–197**

Counseling, in sexual (*continued*)  
 in dyspareunia, 186, 189, 194, 205–217  
 education in, 192–194  
 and guidelines for referrals, 200–201  
 history-taking in, 183–190  
 in impotence, 228–233  
 and masturbation, 198–199  
 physical examination in, 197  
 postmenopausal, 269–277  
 in premature ejaculation, 223–228  
 preventive measures in, 201–202  
 reading material in, 198  
 in vaginismus, 186, 189, 195, 218–220  
 for sexually active young women, 235–248  
 and attitudes of patient, 237–238  
 and attitudes of physician, 236–237  
 and contraception choice, 246–248  
 and dealing with problems of patient, 242–246  
 history-taking in, 238–240  
 pelvic examination in, 240–242  
 time factors in, 170  
 understanding as factor in, 168–169  
 unrealistic expectations in, 172

**Cramps, menstrual.** *See* Dysmenorrhea

**Creatinine**  
 in amniotic fluid, and fetal maturity, 550  
 clearance test  
 in pregnancy, 628  
 in renal disease, 406  
 serum levels in renal disease, 415

**Crotamiton**, antipruritic effects of, 987

**Cryosurgery**  
 in condyloma acuminatum, 1072  
 in vulvar diseases, 979–980

**Culture specimens**, in vulvar disease, 969–970

**Curettage**, in vulvar diseases, 965–966

**Cushing's disease**, hyperprolactinemia in, 132

**Cutaneous vulvar conditions**  
 infections, 957–958, 996–1002  
 inflammations, 991–996

**Cyst**  
 Bartholin's  
 marsupialization in, 966, 975–977  
 Word catheter in, 973, 977  
 pelvic, ultrasonic diagnosis in pregnancy, 326  
 polycystic ovarian disease, 99–112  
 polycystic renal disease in pregnancy, 420

**Cystocele**, and urinary incontinence, 759–773

**Cystography**, in pregnancy, 939

**Cystometry**  
 direct electronic, 695–703  
 gas, 679–683, 713

**Cystometry** (*continued*)  
 and metallic bead-chain  
 urethrocystography, 725–735, 778, 789–790  
 postpartum, 867–869  
 standard water, 669–671, 790–791  
 videocystourethrography, 715–720

**Cytogenetics**, 331–336

**Cytologic studies**, in vulvar disease, 967

**Cytomegalovirus infection**, in pregnancy, 479–480

**Death in utero**  
 and  $\alpha$ -fetoprotein levels, 345  
 and misdiagnosis of FHR, 564  
 and placental lactogen levels, 369  
 ultrasonic diagnosis of, 321–322

**Dehydroepiandrosterone**  
 clearance studies in hypertension with pregnancy, 633  
 loading tests in pregnancy, 360  
 in hypertension, 632  
 plasma levels in childhood, 1143  
 production in normal females, 116

**Dermatitis of vulva**  
 contact, 1002–1004  
 herpetiformis, 1019, 1020  
 neurodermatitis, 995–996  
 seborrheic, 994

**Dessication surgery**, in condylomata acuminata, 978

**Detrusor muscle**, 666  
 activity in urinary incontinence, 673–678, 685–690, 699–701  
*cystometric studies of function. See Cystometry*  
 dyssynergia of, 675, 677–678, 742–743  
 partial bladder denervation for, 797–805  
 innervation of, 662–665  
 uninhibited contraction of, 676–677  
 volitional suppression of reflex in, 687

**Dexamethasone with clomiphene**, for ovulation induction, 156

**Diabetes**  
 and impotence, 230  
 in pregnancy, 443–451, 899  
 bacteriuria in, 923  
 classification of, 445–446  
 delivery in, 451  
 detection and diagnosis of, 446–447  
 and estriol analysis, 356, 360  
 management of, 447–451  
 and maternal morbidity and mortality, 445  
 and maturation of fetal lungs, 450, 556

**Diabetes, in pregnancy (continued)**  
 pathophysiology of, 444  
 and perinatal morbidity and mortality, 444–445  
 placental lactogen levels in, 364, 368  
 renal function in, 420  
 and ultrasonic studies of fetus, 320

**Diazepam, in labor, 497**

**Diazoxide, in hypertension with pregnancy, 638**

**Dichlorphenamide, in hypertension with pregnancy, 640**

**Diet. See Nutrition**

**Diethylstilbestrol, maternal use of, and counseling of daughters, 246**

**Diuretics**  
 in hypertension with pregnancy, 640–644  
 in preeclampsia-eclampsia, 893  
 in pregnancy, affecting fetus, 433

**Diverticula, urethral, 752–753**

**Divorced persons, counseling of, 259–266**

**Donovan bodies, smears for identification of, 971**

**Douching procedures, 242**

**Down's syndrome, chromosome pattern in, 331, 333–334**

**Drug-induced conditions, and sexual problems, 195, 232**

**DTIC therapy, in melanoma, 1126**

**Duchenne's muscular dystrophy, prenatal diagnosis of, 330, 335**

**Duodenal atresia, ultrasound in prenatal diagnosis of, 319**

**Dye-light therapy, in vulvar herpes, 984**

**Dysmenorrhea, 139–144, 242–243**  
 characteristics of, 139  
 pathophysiology of, 139–141  
 treatment of, 141–144

**Dyspareunia, 186, 189, 194, 205–217**  
 counseling in, 245  
 definition of, 205–206  
 etiology of, 206–212  
 Kegel's exercises in, 214, 215–216  
 management of, 212–217  
 organic factors in, 208–210  
 postmenopausal, 275  
 psychogenic factors in, 210–212  
 management of, 212–214  
 vaginal self-dilation methods in, 215–217

**Dysplasia, of vulva, 1087–1090**

**Dystrophies, vulvar, 1025–1029, 1081–1104**

**Eclampsia. See Preeclampsia-eclampsia**

**Ecthyma, of vulva, 1001**

**Edema, in preeclampsia-eclampsia, 886**

**Educational programs**  
 failures of, and adolescent pregnancies, 1154–1155  
 for family life, in adolescence, 1154, 1200–1202

**Ehlers-Danlos syndrome, in pregnancy, 900**

**Eisenmenger syndrome, pregnancy in, 437**

**Ejaculation**  
 premature, 223–228  
 etiology of, 225–226  
 therapy of, 226–228

**retrograde, 230**  
 from phenothiazines, 227, 232

**Electrocardiography of fetal heart rate**  
 abdominal wall approach in, 567–568  
 direct technique in, 563–566

**Electromyography, of urethral sphincter, 672–673, 683–684, 720–721**

**Electrosurgery, in vulvar diseases, 977–978**

**Embolism, amniotic fluid, and fibrinogen degradation products in serum, 348**

**Emotional factors. See Psychogenic factors**

**Empty sella syndrome, anovulation in, 93**

**Encephalitis, Venezuelan equine, in pregnancy, 483–484**

**Endocrinology, 15–161**  
 action of reproductive hormones, 53–66  
 androgen metabolism, 115–122  
 anovulation, 87–95  
 dysmenorrhea, 139–144  
 menstrual cycle regulation, 17–28  
 ovarian function, 31–51  
 in adolescence, 1144  
 ovulation induction, 147–161  
 polycystic ovarian disease, 99–112  
 prolactin metabolism, 125–135  
 pubertal development, 67–85, 1143–1144  
 energy requirements, in pregnancy, 298–299  
 in adolescence, 1205

**Erosions, vulvar, 959–960**

**Erysipelas, of vulva, 1001**

**Erythema multiforme, of vulva, 1017–1019, 1020**

**Erythrasma, of vulva, 999–1000**  
 scrapings of material in, 971  
 Wood's light studies in, 968

**Erythroblastosis fetalis, management of, 606**

**Estriol analysis in pregnancy, 353–361**  
 and dehydroepiandrosterone sulfate-loading tests, 360–361

**serum, 357–360**  
**urinary, 355–357**  
 in diabetes, 356  
 in fetal growth retardation, 356  
 in hypertension, 356–357

Estriol analysis, urinary (*continued*)  
  in postmaturity, 356

Estrogens  
  and central nervous system function, 22–23  
  in corpus luteum, 48  
  deficiency of  
    and sexual problems, 195  
    and urinary incontinence, 747, 749, 762  
  and ovulation induction, 149, 154–156  
  postmenopausal use of, 275–277  
  and premature labor, 534  
  production from androgens, 58, 110, 122  
  and prolactin levels, 127, 133  
  receptors for  
    in brain tissue, 22  
    in ovarian cells, 34  
  serum levels of, 74  
    in hypertension with pregnancy, 632  
    in polycystic ovarian disease, 102–104  
    in puberty, 1144  
  as therapy in vulvar diseases, 987, 1104  
  “two cell” theory of synthesis of, 44, 58

Ethacrynic acid, in hypertension with  
  pregnancy, 641

Ethanol. *See* Alcohol

Examination  
  pelvic, in sexually active young women,  
    240–242  
  premarital, new approach to, 255–256

Excision, of vulvar lesions, 966, 973–975

Expectations, unrealistic  
  and changes in lifestyle, 266  
  in counseling, 172  
  and sexual problems, 186, 189

Fallot's tetralogy, pregnancy in, 436–437

Family life, education for, in adolescence,  
  1154, 1200–1202

Family relationships, and adolescent  
  pregnancies, 1163–1164

Females. *See* Women

$\alpha$ -Fetoprotein assay, 330, 342–346  
  in absence of fetus, 346  
  abortion affecting, 344  
  in complications of pregnancy, 345  
  fetal death affecting, 345  
  in multiple gestation, 345  
  in Rh disease, 345.

Fetoscopy, 330

Fetus  
  acidosis of  
    primary, during hypoxia, 579–580  
    secondary, 581  
  agents affecting  
    anticoagulants, 433

Fetus, agents affecting (*continued*)  
  corticosteroids, 388, 466  
  diuretics, 433  
  alkalosis of, secondary, 581  
  androgen metabolism in, 120  
  biparietal diameter of, 312  
  cephalopelvic disproportion, and breech  
    presentation, 527  
  death in utero. *See* Death in utero  
  endocrine development in, 67–69  
  growth retardation in. *See* Growth  
    retardation  
  heart rate monitoring in, 375–383, 561–576.  
    *See also* Heart rate monitoring

maternal diseases affecting  
  cytomegalovirus, 480  
  diabetes, 444  
  herpes, 477–479, 1016, 1057  
  streptococcal infections, 466–467  
  varicella, 481

maturity evaluation, 547–558  
  amniotic fluid measurements in, 550  
  biochemical measurements in, 549  
  bubble stability test in, 554  
  and creatinine in amniotic fluid, 550  
  and lecithin/sphingomyelin ratio in  
    amniotic fluid, 450, 553–555  
  and lung development, 550–557. *See also*  
    Lung development  
  Nile blue sulfate test in, 550  
  radiology in, 549  
  ultrasound in, 312, 549

nutritional needs of, 297–309  
  and effects of dietary deficiency, 303–305  
  and effects of dietary supplementation,  
    306–307

prenatal diagnosis of disorders. *See* Prenatal  
  diagnosis

protein synthesis in, 300–301

scalp blood analysis, 582–585  
  oxygen values in, 589–590

ultrasonic studies of, 311–322, 330. *See also*  
    Ultrasound in obstetrics

Fibrinogen, degradation products measured in  
  pregnancy, 347–350

in eclampsia, 348–349

in preeclampsia, 349–350

Fluid and electrolyte therapy, in  
  preeclampsia-eclampsia, 891

Flumethiazide, in hypertension with  
  pregnancy, 640

Fluorescence studies, with Wood's light, in  
  vulvar disease, 968

5-Fluorouracil  
  in condyloma acuminatum, 1072

5-Fluorouracil (*continued*)  
 in vulvar diseases, 988

Follicle development, ovarian, 31–44

Follicle-stimulating hormone  
 action of, 54–60  
 and aromatase activity in granulosa cells, 41  
 in fetal circulation, 67  
 in follicular fluid, 40  
 formation of, 25  
 and induction of LH receptors, 42  
 receptors in granulosa cells, 32–34  
 serum levels of, 74  
 in infancy and childhood, 69  
 in polycystic ovarian disease, 104–106  
 in puberty, 1145

Follicular fluid  
 formation of, 36–41  
 hormones in, 40–41  
 plasminogen in, 47–48

Folliculitis, of vulva, 1001

Fox–Fordyce disease, estrogen therapy in, 987

Freckle, Hutchinson's, 1120

Frei skin test, in lymphogranuloma venereum, 971

Friends of formerly married persons,  
 relationships with, 260–261

Fulguration, in condylomata acuminata, 978

Furosemide, in hypertension with pregnancy, 641

Furuncles, of vulva, 1001

Galactorrhea, and hyperprolactinemia, 129–133

Ganglionic blocking agents, in hypertension with pregnancy, 644

Gastrointestinal lesions, ultrasound in prenatal diagnosis of, 319

Genetic disorders, prenatal diagnosis of, 329–339  
 and counseling of parents, 336–337

Gentian violet, in candidiasis of vulva, 973, 983

Glomerular filtration rate, 846  
 in pregnancy, 412–413, 856, 938  
 in renal disease, 414

Glomerulonephritis, in pregnancy, 418–419, 879–880, 896–898

Glucose  
 metabolism in pregnancy, 443–444  
 serum levels of, and placental lactogen secretion, 364

Glucosuria, in pregnancy, 856, 899

Glycoprotein levels in pregnancy  
 $\alpha$ -2-glycoprotein, 347

Glycoprotein (*continued*)  
 $\beta$ -1-glycoprotein, 346

Goltz's syndrome, 1070

Gonadotropins  
 human chorionic, 25, 54  
 and ovulation induction, 149, 153–154, 156–159  
 human menopausal, and ovulation induction, 149, 156–159

pituitary, 54. *See also* Follicle-stimulating hormone; Luteinizing hormone  
 composition of, 25  
 metabolism of, 25–27  
 and ovarian cycle, 24–25  
 in polycystic ovarian disease, 104–106  
 secretion in childhood, 69, 1145  
 serum levels of, 25–27, 74

Gonorrhea  
 counseling in, 244  
 culture specimens in, 969  
 smears in, 970

Granuloma inguinale, 1041–1043  
 clinical aspects of, 1042–1043  
 diagnosis of, 1043  
 smears in, 971  
 treatment of, 1043

Granulosa cells  
 aromatase activity in, 41  
 gap junctions in, 35–36  
 luteinized, 48  
 receptors in, 32–35, 42

Group sessions  
 premarital, 255–256  
 and relational health promotion, 256

Growth patterns, in puberty, 1137–1140

Growth retardation, intrauterine  
 and breech presentations, 516–519  
 and estriol analysis  
 in plasma, 360  
 in urine, 356  
 in hypertension, 399  
 in malnutrition, 303–307  
 placental lactogen levels in, 367–368  
 ultrasonic recognition of, 312–313

Guancydine, in hypertension with pregnancy, 638

Guanethidine, in hypertension with pregnancy, 637

Guilt  
 alleviation of, in formerly married persons, 264–265  
 sexual, 186

Gynecologists. *See* Physicians

Gynecomastia, and hyperprolactinemia, 133

Hailey-Hailey syndrome, 1011, 1020, 1036  
 Health care for women, changing attitudes in, 173-180  
 Health promotion, relational, 256  
 Heart  
   diseases in pregnancy, 429-440. *See also*  
     Cardiovascular disease  
   in preeclampsia-eclampsia, 885  
   valvular prostheses, pregnancy risks with, 438-439

Heart rate monitoring, fetal, 375-383, 561-576  
   acceleration patterns in, 573  
   baseline in, 572-573  
   classification of patterns and  
     pathophysiology of, 571-572  
   contraction stress test in, 376, 377-378  
     combined with non-stress test, 379-383  
   and death in utero, 564  
   deceleration patterns in, 573-574  
   direct technique for, 563-566  
   effect on perinatal outcome, 574-576  
   electrocardiography in  
     abdominal wall, 567-568  
     direct, 563-566  
   in hypertension with pregnancy, 633-634  
   indirect techniques in, 566-568  
   instrumentation in, 561-562  
   non-stress testing in, 376, 378-379  
     combined with contraction stress test, 379-383  
   periodic FHR in, 573-574  
   phonocardiography in, 567  
   ultrasonography in, 566-567  
   asnd uterine activity display, 566

Hemolytic anemia, autoimmune, in pregnancy, 390

Hemolytic disease of newborn, management of, 606

Hemophilia A, prenatal diagnosis of, 335

*Hemophilus ducreyi*, smears for identification of, 970

Henle's loop, 828

Hepatitis B infection, in pregnancy, 482-483

Herpesvirus infections  
   of newborn, 478, 1057-1058  
   in pregnancy, 1015-1017  
     herpes simplex, 477-479  
     herpes zoster, 480-482  
   of vulva, 1053-1059  
     betadine in, 983-984  
     and carcinoma, 1058  
     clinical aspects of, 1056-1057  
     culture specimens in, 970  
     dye-light therapy in, 984  
     laboratory studies in, 1055

Herpesvirus, of vulva (*continued*)  
   laser therapy in, 981-982  
   perinatal aspects of, 1057-1058  
   recurrent, 1057  
   serologic tests for, 969  
   smears in, 971  
   therapeutic considerations in, 1058-1059

High-risk pregnancy  
   and autoimmune disorders, 385-393  
   blood protein levels in, 341-350  
   cardiac diseases in, 429-440  
   diabetes in, 443-451  
   estriol analysis in, 353-361  
   fetal heart rate monitoring in, 375-383, 561-576  
   and management of hypertension, 397-408  
   placental lactogen levels in, 363-371  
   and prenatal risk assessment, 287-294. *See also* Prenatal diagnosis  
   renal disease in, 414-425  
   and role of pediatrician, 593-606

Hirsutism  
   androgen metabolism in, 121-122  
   in heterosexual precocity, 79  
   in polycystic ovarian disease, 99, 122

History-taking  
   and counseling of sexually active young women, 238-240  
   in sex counseling, 183-190

Hormone therapy, in vulvar diseases, 984-987

Hormones, reproductive, 53-66  
   peptides, 54-60  
   steroids, 61-66

Hurler's syndrome, in pregnancy, 900

Hutchinson's freckle, 1120

Hyaline membrane disease, and fetal lung maturation. *See* Lung development in fetus

Hydralazine  
   in hypertension with pregnancy, 401, 638  
   in preeclampsia-eclampsia, 892-893

Hydramnios, fluffy fetus with, 320

Hydrocephalus, ultrasound in prenatal diagnosis of, 315

Hydrochlorothiazide, in hypertension with pregnancy, 640

Hydrogen ion secretion, in kidney, 851-852

Hydronephrosis, ultrasound in prenatal diagnosis of, 319

Hydroureter, in pregnancy, 857-861

Hydroxyprogesterone caproate, in management of premature labor, 537

Hymeneal strand, and sexual problems, 196

Hyperparathyroidism, in pregnancy, 914

Hypertension in pregnancy, 397–408, 619–646, 881–882  
 adrenergic blocking agents in, 636–638  
 ambulatory care in, 403  
 amniotic fluid analysis in, 631  
 arteriolar dilators in, 638–639  
 blood chemistry in, 629–630  
 cardiovascular studies in, 627–628  
 characteristics of, 624  
 classification of, 620–622  
 control of blood pressure in, 401  
 dehydroepiandrosterone loading studies in, 632  
 dehydroepiandrosterone sulfate clearance studies in, 633  
 diuretics in, 640–644  
 endocrine studies in, 629  
 and estriol analysis  
   in plasma, 360  
   in urine, 356–357  
 estrogen levels in, 632  
 and evaluation of fetal-placental unit, 630–634  
 and evaluation of patient, 625–630  
 fetal heart monitoring in, 633–634  
 and fetal lung maturation, 402  
 and  $\alpha$ -fetoprotein levels, 345  
 ganglionic blocking agents in, 644  
 hospitalization in, 404–408  
 with immature fetus, 398–399  
 incidence of, 622–624  
 laboratory studies in, 627–630  
 with mature infant, 397–398  
 physical examination in, 626–627  
 placental enzyme studies in, 631–632  
 placental lactogen assay in, 366, 633  
 and preeclampsia-eclampsia, 886, 889  
 prevention of convulsions in, 399–401  
 prognosis of, 624–625  
 pulmonary hypertension, 437–438  
 renovascular studies in, 628–629  
 screening tests in prediction of, 403  
 social evaluation in, 630  
 therapy in, 634–645  
 ultrasonography in, 630  
 veratrum alkaloids in, 644

Hypertrophic disorders, of vulva, 1033–1037

Hypnosis, for pain relief in labor, 496

Hypogonadism  
 hypergonadotropic, 81–83  
 hypogonadotropic, 83–84

Hypothalamus  
 defects causing anovulation, 93–95  
 function in adolescence, 1145–1146  
 lesions with hyperprolactinemia, 130–131

Hypothalamus (*continued*)  
 release of LHRH, 21–22, 54

Hypothermia in newborn, management of, 602–603

Hypothyroidism  
 hyperprolactinemia in, 132  
 and precocious puberty, 77

Hypoxia, and fetal acidosis, 579–580

Immune serum globulin  
 in hepatitis B, 483  
 in varicella, 482

Immunofluorescence studies  
 in dermatitis herpetiformis, 1019  
 in herpes gestationis, 1016–1017  
 in pemphigoid of vulva, 1013, 1015  
 in pemphigus, 1010  
 in vulvar bullous disease, 966–967

Immunology  
 and autoimmune disorders, 385–393  
 and condyloma acuminatum, 1062–1064  
 and host defense mechanisms in pregnancy, 455–456  
 and maternal transmission of IgG, 300

Immunotherapy  
 in condyloma acuminatum, 1063–1064, 1072–1076  
 in melanoma, 1126–1127  
 in vulvar diseases, 988

Impetigo, of vulva, 1001

Impotence, 228–233  
 physical causes of, 229–232  
 prosthetic implants in, 233  
 psychogenic causes of, 229, 232–233

Incontinence, urinary, 649–815. *See also*  
 Urinary incontinence

Indomethacin, in management of premature labor, 539

Infections in pregnancy  
 bacterial, 455–473  
 urinary tract, 422–424  
 viral, 477–486

Infertility, anovulatory. *See* Anovulation

Insulin therapy, in diabetes in pregnancy, 449

Intertrigo, of vulva, 1033

Intubation, tracheal, of newborn, 598–600

Iron  
 dietary requirements in pregnancy, 308  
 in adolescence, 1206  
 therapy in pregnancy, 432

Isoxsuprine, in management of premature labor, 538

Kallman's syndrome, anovulation in, 94

Karyotypes, normal, 331, 332

Kegel's exercises, in dyspareunia, 214, 215–216

Keratinocytes, 1118

17-Ketosteroids, urinary, in childhood, 1143

Kidney

- and acid-base homeostasis, 851–852
- acute failure in pregnancy, 421–422, 875–877, 901–904
- agenesis of
  - bilateral, 832–833
  - unilateral, 833–834
- anatomy of, 825–826, 828
- anomalies of, 832–842
- blood flow in, 845
  - in pregnancy, 939
- blood supply of, 826–827
- disorders in pregnancy, 414–425, 875–880, 894–904
  - biopsy in, 416–418
  - in diabetes, 420
  - diagnostic tests in, 937–944
  - fetal surveillance in, 418
  - function tests in, 416
  - maternal surveillance in, 416–418
  - pathophysiology of, 414–415
- ectopia of, 839
  - crossed, 840
- embryology of, 819–822, 831–832
- function tests, 937–939
  - in pregnancy, 416
- fused, pelvic, 839–840
- glomerular filtration in, 846
  - in pregnancy, 412–413, 856, 938
- glomerulonephritis in pregnancy, 418–419, 879–880, 896–898
- horseshoe, 841–842
- hypoplasia of
  - dysplastic, 836
  - unilateral, 834–836
- innervation of, 828
- lupus nephritis in pregnancy, 387, 419
- nephrotic syndrome in pregnancy, 419–420, 879, 898–899
- polycystic disease in pregnancy, 420
- postpartum renal failure, 422
- potassium handling in, 850–851
- in preeclampsia, 877–878, 884, 889–890
- in pregnancy, 411–414, 855–857, 907–908
- single, with double pelvis, 837–839
- sodium handling in, 848–850
- supernumerary, 839
- transplantation of, pregnancy after, 421, 931–934
- trauma in pregnancy, 918
- tuberculosis in pregnancy, 420, 895–896

Kidney (*continued*)

- tubular function in pregnancy, 413
- ultrasound in prenatal diagnosis of lesions, 319
- urine concentration and dilution in, 846–848
  - in pregnancy, 939
- urolithiasis in pregnancy, 420, 912–914, 927–928

Koebner phenomenon, in lichen planus, 993

Kraurosis vulvae. *See* Lichen sclerosus of vulva

Labor

- anesthesia in, 489–504
- breech presentation in, 511–531
- cardiovascular alterations in, 431
- in diabetes, 451
- management in hypertension, 401–403
- monitoring in
  - of fetal heart rate, 375–383, 561–576
  - of uterine activity, 569–571
- pain in, 491–492
- premature, management of, 533–542
- and role of pediatrician, 596–603

Lactogen, placental, 363–371

- assay in hypertension with pregnancy, 366, 633
- function of, 363–364
- serum levels of, 364–370
  - in diabetes, 364, 368
  - factors affecting, 364–365
  - in fetal anomalies, 369
  - in fetal death, 369
  - in fetal growth retardation, 367–368
  - for gestational dating, 366
  - and management of high risk pregnancies, 370
  - in postmaturity syndrome, 368–369
  - in threatened abortions, 365–366
  - in toxemia and hypertension, 366

Laminaria tents, for abortion in teenagers, 1185–1187

Laser therapy

- in condyloma acuminatum, 981, 1072
- in vulvar diseases, 980–982

Laurence-Moon-Biedl syndrome, anovulation in, 94

Lecithin/sphingomyelin ratio, in amniotic fluid, 553–555

- in hypertension with pregnancy, 631
- in infants of diabetics, 450

Legal problems, and abortion in teenagers, 1181

Leiomyoma, uterine, ultrasonic diagnosis in pregnancy, 326

Lentigo maligna, 1120

Leriche syndrome, impotence in, 230

Leukoplakia, vulvar, 1081. *See also Vulva, white lesions of*

Libido, in menopause, 270

Lichen

- planus, of vulva, 993–994, 1029
- sclerosus, of vulva, 1025–1028, 1090–1095
  - in children, 1104
  - with epithelial hyperplasia, 1095
  - laser therapy in, 981
  - testosterone propionate ointment in, 984–986
  - treatment of, 1101–1102
- simplex chronicus, of vulva, 995–996, 1033, 1035, 1083

Lifestyle changes, in formerly married persons, 265–266

Listening, and counseling, 168
 

- in sexual problems, 192

Liver, in preeclampsia-eclampsia, 885

Loneliness, in formerly married persons, 260

Lung development in fetus, 550–557
 

- acceleration in, 555–557
- corticosteroids affecting, 466, 542, 557–558
- deceleration in, 556
- in infants of diabetics, 450
- maternal hypertension affecting, 402
- and surfactant activity, 552–553

Lupus erythematosus, in pregnancy, 900

Lupus nephritis, in pregnancy, 387, 419

Luteinization, of granulosa cells, 48

Luteinizing hormone

- action of, 54–60
- in fetal circulation, 67
- in follicular fluid, 41
- mid-cycle surge of, 25, 148
- receptor induction by FSH, 42
- releasing hormone
  - action of, 54–60
  - measurements and dynamics of, 23–24
  - and ovulation induction, 159–160
  - release from hypothalamus, 21–22, 54
  - responses to, in polycystic ovarian disease, 105–106
- serum levels of, 74
  - in infancy and childhood, 69
  - in polycystic ovarian disease, 104–106
  - in puberty, 1145

Luteolysis, 48–51

Lymphatics, of urinary system, 830

Lymphogranuloma venereum, 1043–1046
 

- clinical aspects of, 1044–1045
- culture specimens in, 970
- diagnosis of, 1045
- Frei skin test in, 971

Lymphogranuloma venereum (*continued*)

- serologic tests for, 969
- smears in, 970, 971
- treatment of, 1046

Lysozyme in cervical mucus, antibacterial effect of, 457–458

$\alpha$ -2-Macroglobulin, 347

Magnesium

- intake in adolescent pregnancy, 1206
- therapy with vitamin B<sub>6</sub> in dysmenorrhea, 141–142

Magnesium sulfate therapy

- in hypertension with pregnancy, 399–401
- in preeclampsia-eclampsia, 892
- in premature labor, 539

Male sexual problems, gynecologic implications of, 223–233

Malnutrition, and fetal growth and development, 303–307

Mammographic screening, 1–13
 

- compared to diagnostic evaluation, 2
- false negatives in, 3–4, 9
- false positives in, 4, 9
- guidelines in, 12
- problems of, 3–11
- radiation dosage in, 4, 7
- and self-selection of screeners, 6, 11

Manganese deficiency, in pregnancy, 308–309

Mannitol, in hypertension with pregnancy, 640

Marfan's syndrome, in pregnancy, 435–436, 900

Marriage

- and counseling of couples, 249–257
- and counseling of formerly married, 259–266

Marsupialization, in Bartholin cysts and abscesses, 966, 975–977

Masturbation, attitudes toward, 198–199

Maturation of fetus, evaluation of, 547–558

McCune-Albright syndrome, 77

Meconium aspiration syndrome, 605

Melanocytes, 1118

Melanoma, 1117–1132
 

- classification of, 1120–1122
- and cutaneous microanatomy, 1117–1120
- lentigo malignant, 1120
- nodular, 1122
- prognosis of, 1123–1125
- superficial spreading, 1122
- treatment of, 1125–1127
- vulvar, 1127–1131

Melanosomes, 1118

Membrane rupture, premature infections in, 462–466

Membrane rupture (*continued*)  
     management of, 539

Menarche, 72–73, 109, 1142–1143

Menometrorrhagia, pubertal, 84–85

Meningomyelocele, ultrasound in prenatal diagnosis of, 317

Menopause, and sexual problems, 269–277

Menstrual cramps. *See* Dysmenorrhea

Menstrual cycle regulation, 17–28

Meperidine, in labor, 497

Mercurophyllin, in hypertension with pregnancy, 640

Mesonephros, 820, 831

Metabolism, in pregnancy, 443–444

Metanephros, 821–822, 832

Methazolamide, in hypertension with pregnancy, 640

Methyldopa, in hypertension with pregnancy, 637

Microcephaly, ultrasound in prenatal diagnosis of, 315

Minoxidil, in hypertension with pregnancy, 638

Mitral stenosis, pregnancy with, 439–440

Molar pregnancies, ultrasonic diagnosis of, 323–326

Molluscum contagiosum, smears in, 971

Monitoring procedures  
     for fetal heart rate, 375–383, 561–576. *See also* Heart rate monitoring  
     in labor, logic and editing systems in, 568  
     and postpartum infections, 467–473  
     and scalp blood analysis in fetus, 582–585  
     for uterine activity in labor, 569–571  
         catheterization in, intrauterine, 569  
         display with fetal heart rate, 566  
         tocodynamometry in, 569

Mortality  
     in abortions in adolescence, 1176–1178  
     in breech presentations, 521–523  
     in diabetes, 444–445

Multiple gestation  
      $\alpha$ -fetoprotein levels in, 345  
     lung development in, 555  
     placental lactogen levels in, 369  
     ultrasonic signs of, 314–315

Muscular dystrophy, Duchenne type, prenatal diagnosis of, 330, 335

Myasthenia gravis, in pregnancy, 392–393

Mycoplasma infections, culture specimens in, 970

Myoma, uterine, ultrasonic diagnosis in pregnancy, 326

Myometrium, prostaglandins affecting, 140

Narcotics, in labor, 497

Nelson's syndrome, hyperprolactinemia in, 132

Neonatal conditions. *See* Newborn

Nephritis, lupus, in pregnancy, 387, 419

Nephrostomy, percutaneous, 915

Nephrotic syndrome, in pregnancy, 419–420, 879, 898–899

Nervous system, central  
     defects causing anovulation, 91–95  
     and reproductive function, 20–24

Neural control, of urethrovesical function, 653–667

Neural tube defects  
     and  $\alpha$ -fetoprotein levels, 342  
     prenatal diagnosis of, 336

Neurodermatitis, of vulva, 995–996

Neurologic disorders, impotence in, 231

Newborn  
     androgen metabolism in, 120  
     Apgar scores for. *See* Apgar scores  
     birthweight of. *See* Birthweight  
     cytomegalovirus infection of, 479–480  
     hemolytic disease of, 606  
     hepatitis B infection of, 482  
     herpes infection of, 478, 1057–1058  
     hypothermia in, management of, 602–603  
     maternal alcohol ingestion affecting, 307  
     meconium aspiration syndrome in, 605  
     resuscitation of, 597–602  
     and role of pediatrician in management, 596–606  
     tracheal intubation of, 598–600  
     varicella infection of, 481

Nile blue sulfate test, for fetal maturity, 550

Nitroprusside, in hypertension with pregnancy, 638

Nutrition, in pregnancy, 297–309  
     in adolescence, 1202–1208  
     and amino acid changes, 301  
     and amniotic fluid properties, 301–303  
     copper deficiency in, 308  
     in diabetes, 448, 449  
     and effects of dietary deficiency, 303–305  
     and effects of dietary supplementation, 306–307  
     and energy requirements, 298–299  
         in adolescence, 1205  
     manganese deficiency in, 308  
     in preeclampsia-eclampsia, 891  
     and protein changes, 299–301  
     trace elements in, 308  
     zinc deficiency in, 308

Obstetricians. *See* Physicians  
 Office practice, counseling in. *See* Counseling  
 Oocytes, maturation of, 32  
 Orgasmic intercourse, frequency in women, 187, 193, 199  
 Ovarian function, 31–51  
   and corpus luteum development, 48–51  
   defects in anovulation, 88–91  
   and fetal development, 67–69  
   follicle development in, 31–44  
     differentiation in, 32–42  
     and gap junction in granulosa cells, 35–36  
     primary follicles, 32–36  
     primordial growth initiation, 31–32  
     and receptors in granulosa cells, 32–35, 42  
     secondary follicles, 36–42  
       and theca interna development, 36  
     and follicular atresia, 42–44  
     and follicular rupture, 44–47  
     gonadotropins affecting, 24–25  
     in ovulation, 44–48  
     in polycystic disease, 99–112  
     and premature failure, 88  
     prolactin affecting, 27  
     in puberty, 1144  
 Ovarian vein syndrome, in pregnancy, 910–912  
 Ovulation, 44–48  
   and anovulation pathophysiology, 87–95  
   induction of, 147–161  
   agents in, 149, 153–160  
   bromocriptine in, 135, 160  
   clomiphene in, 149, 153–156, 159  
   estrogens in, 149, 154–156  
   hazards in, 151–153  
   human chorionic gonadotropin in, 149, 153–154, 156–159  
   human menopausal gonadotropin in, 149, 156–159  
   long-term residual effects of, 153  
   pretreatment evaluation in, 147  
   releasing hormones in, 159–160  
   therapies approved for use in U.S., 153–159  
   therapies not approved for use in U.S., 159–160  
   treatment plan in, 150–151  
   physiology and pharmacology of, 148–149  
 Oxygen  
   and fetal acidosis in hypoxia, 579–580  
   and fetal asphyxia in breech presentations, 520, 523  
   values in fetal scalp blood, 689–690

Oxytocin  
   challenge test in fetal heart rate monitoring, 376, 377–378  
   combined with non-stress test, 379–383  
   release of, and premature labor, 534

Page's disease of vulva, 1107–1114  
   clinical findings in, 1110–1112  
   5-fluorouracil in, 988  
   histologic findings in, 1112  
   theories for origin of, 1113–1114

Pain  
   in labor, 491–492  
   menstrual. *See* Dysmenorrhea  
   pelvic, in sexually active young women, 245  
   and sexual problems. *See* Dyspareunia  
 Papaverine, in hypertension with pregnancy, 638

Parathyroid gland, and hyperparathyroidism in pregnancy, 914

Pargyline, in hypertension with pregnancy, 637

Parkinsonism, hyperprolactinemia in, 132

Patch testing, in vulvar disease, 968, 1003

Pediatrician, in management of high-risk pregnancy, 593–606  
   in antenatal period, 593–596  
   in intrapartum and immediate neonatal period, 596–603  
   in postpartum period, 603–605  
   special problems in, 605–606

Pediculosis pubis, diagnosis of, 971

Pelvic examination, in sexually active young women, 240–242

Pelvic fracture, in pregnancy, 918

Pelvic ganglia, and neural control of urethrovesical function, 660–662

Pelvic relaxation  
   and sexual problems, 196  
   and urologic problems, 759–773

Pemphigoid, of vulva, 967  
   benign mucous membrane, 1014–1015, 1020  
   bullosum, 1013–1014, 1020

Pemphigus, of vulva, 1007–1013, 1020  
   clinical features of, 1007–1009  
   familial benign chronic, 1011, 1013  
   histology of, 1009–1010  
   immunofluorescence studies in, 1010  
   laboratory findings in, 1009–1010  
   treatment of, 1010  
   vegetans, 1008  
   vulgaris, 967, 1007–1008

Periarteritis nodosa, in pregnancy, 389–390, 419, 900

Perinatal medicine, risk assessment in, 287-294

pH, and maternal-fetal acid-base relationships, 585-589

Phenothiazines, retrograde ejaculation from, 227, 232

Phenoxybenzamine, in hypertension with pregnancy, 637

Pheochromocytoma, in pregnancy, 629

Phonocardiography, in monitoring of fetal heart rate, 567

Phospholipids, in amniotic fluid, and fetal maturation evaluation, 550

Phosphorus intake, in adolescent pregnancy, 1206

Physicians  
  changing relationships with patients, 173-180  
  counseling by. *See* Counseling  
  pediatricians in management of high-risk pregnancy, 593-606

Pituitary gland  
  defects causing anovulation, 91-93  
  function in adolescence, 1145-1146  
  gonadotropins of. *See* Gonadotropins and reproductive function, 24-27  
  tumors of, hyperprolactinemia in, 131

Placenta  
  abruption of  
    and fibrinogen degradation products in serum, 348  
  ultrasonic diagnosis of, 323  
  aspiration of cells in, 330  
  in breech presentations, 520  
  enzyme studies in hypertension with pregnancy, 631-632  
  localization with ultrasound, 322-323  
  in preeclampsia-eclampsia, 884  
  previa, ultrasonic signs of, 323  
  transplacental passage  
    of infectious agents, 459-460  
    of proteins, 300

Placental lactogen, 363-371  
  assay in hypertension with pregnancy, 633

Plasminogen, in follicular fluid, 47-48

Podophyllin, in condyloma acuminatum, 987, 1070-1071

Polyarteritis, in pregnancy, 389-390, 419, 900

Polyclastic kidney disease, in pregnancy, 420

Polycystic ovarian disease, 99-112  
  androgen levels in, 100-102  
  estrogen levels in, 102-104  
  etiological factors in, 108-112  
  gonadotropin levels in, 104-106  
  hirsutism in, 99, 122

Polycystic (*continued*)  
  pathophysiology of anovulation in, 106-108  
  symptoms of, 99-100

Postmaturity  
  and estriol analysis in urine, 356  
  placental lactogen levels in, 368-369

Potassium, renal handling of, 850-851

Potter's syndrome, 832-833

Povidone-iodine, in vulvar lesions, 983-984

Prazosin, in hypertension with pregnancy, 638

Precocious puberty, 75-81

Preeclampsia-eclampsia, 881-894  
  blood changes in, 885  
  blood vessels in, 884  
  brain in, 885  
  and control of eclampsia, 399-402  
  diet in, 891  
  edema in, 886  
  etiology of, 882  
  and fibrinogen degradation products in serum, 348-350  
  fluids and electrolytes in, 891  
  α-2-glycoprotein levels in, 347  
  heart in, 885  
  hypertension in, 886, 889. *See also* Hypertension in pregnancy  
  incidence of, 883-884  
  liver in, 885  
  magnesium sulfate in, 892  
  pathogenesis of, 884-888  
  placenta in, 884  
  prognosis of, 893-894  
  proteinuria in, 888  
  renal lesions in, 877-878, 884, 889-890  
  sedatives in, 891-892  
  sodium retention in, 887-888  
  treatment of, 890-893  
  water retention in, 887  
  weight gain in, 887

Pregnancy  
  in adolescence, 1135-1232. *See also* Adolescence  
  alcohol ingestion in, affecting newborn, 307  
  amino acid levels in  
    in amniotic fluid, 303  
    relation to infant growth, 305  
    in serum, 301  
  autoimmune disorders in, 385-393  
  bacterial infections in, 455-473  
  bacteriuria in, 422-424, 870-871, 879, 921-926  
  blood pressure in, 413, 431  
  blood volume in, 413-414, 431  
  calculi in, urinary, 420, 912-914, 927-928  
  cardiac disease in, 429-440

Pregnancy (*continued*)

- cardiovascular alterations in, 430–431
- cardiovascular surgery in, 433–434
- collagen diseases in, 899–901
- cystography in, 939
- cytomegalovirus infection in, 479–480
- diabetes in, 443–451, 899. *See also* Diabetes
- energy requirements in, 298–299
  - in adolescence, 1205
- estriol analysis in, 353–361
- fetal heart rate monitoring in. *See* Heart rate monitoring
- $\alpha$ -fetoprotein levels in, 342–346
- fibrinogen and degradation products in, 347–350
- glomerular filtration rate in, 412–413, 856, 938
- glomerulonephritis in, 418–419, 879–880, 896–898
- glycoprotein levels in, 346–347
- hemolytic anemia in, autoimmune, 390
- herpes infection in, 477–479, 1015–1017
  - affecting infant, 1057–1058
- hyperparathyroidism in, 914
- hypertension in, 397–408, 619–646, 881–882.
  - See also* Hypertension in pregnancy
  - kidney changes in, 411–414
- kidney disorders in, 414–425, 875–880, 894–904
  - diagnostic tests in, 937–944
- lupus nephritis in, 387, 419
- metabolism in, 443–444
- molar, ultrasonic diagnosis of, 323–326
- multiple. *See* Multiple gestation
- myasthenia gravis in, 392–393
- nephrotic syndrome in, 419–420, 879, 898–899
- nutrition in, 297–309
  - in adolescence, 1202–1208
- ovarian vein syndrome in, 910–912
- polyarteritis in, 389–390, 419
- preeclampsia-eclampsia in, 877–878, 881–894
- prolactin levels in, 128
- protein levels in
  - in amniotic fluid, 301–302
  - relation to infant growth, 305
  - in serum, 299–300, 341–350
  - in urine, 398, 413, 879–880, 888, 938
- pyelography in, intravenous, 939
- radioisotope renogram in, 941–943
- renal angiography in, 940
- renal plasma flow in, 939
- in renal transplant recipients, 421, 931–934
- rheumatoid arthritis in, 385–386, 900

Pregnancy (*continued*)

- and risk assessment in perinatal medicine, 287–294
- rubella in, 484–485
- sclerosis in, progressive systemic, 389, 419
- thrombocytopenic purpura in, autoimmune, 391–392
- and trauma to urinary tract, 917–918
- ultrasound techniques in, 311–326, 330
  - in hypertension, 630
  - in urologic disorders, 943
- ureteropelvic junction obstruction in, 908–910
- ureterovesical reflux in, 863–872, 939
- urinary concentration and dilution in, 939
- urinary tract alterations in, 907–908
- urinary tract infections in, 422–424
  - diagnostic tests in, 937–944
  - urine sediment in, 937
  - urologic surgery in, 907–919
  - varicella in, 480–482
- Venezuelan equine encephalitis in, 483–484
- viral infections in, 477–486
- weight gain in, 413
  - in adolescence, 1205

Premarital examination, new approach to, 255–256

Premature ejaculation, 223–228

Premature rupture of membranes

- infection in, 462–466
- management of, 539

Prematurity

- and breech presentation, 512, 516, 525
- and corticosteroids affecting lung maturation, 466, 542, 557–558
- etiology of, 533–535
- estrogen activity, 534
- fetal corticosteroids, 534
- oxytocin release, 534
- progesterone deprivation, 534
- prostaglandins, 535
- and management of labor, 535–539
- bed rest in, 535
- ethanol in, 535–537
- magnesium sulfate in, 539
- progesterone in, 537
- prostaglandin inhibitors in, 539
- sympathomimetic drugs in, 537–538
- and survival of very low birth weight infants, 542

Prenatal diagnosis of fetal disorders

- amniocentesis in, 330, 336–339
- in Down's syndrome, 331, 333–334
- estriol analysis in, 353–361
- $\alpha$ -fetoprotein assay in, 330, 342–346

Prenatal diagnosis (*continued*)  
 in genetic disorders, 329–339  
 in hemophilia A, 335  
 in muscular dystrophy, 330, 335  
 in neural tube defects, 336  
 in Tay-Sachs disease, 334  
 ultrasonic techniques in, 311–322, 330

Progesterone  
 in corpus luteum, 48  
 in management of premature labor, 537  
 maternal levels of, and premature labor, 534  
 synthesis from cholesterol, 58

Prolactin  
 action of, 54–60  
 control of release, 126  
 factors affecting secretion of, 127  
 in follicular fluid, 41  
 hyperprolactinemia, 127, 129–135  
   bromocriptine in, 135, 160  
   diagnostic studies in, 133–134  
   in hypothalamic disease, 130–131  
   in hypothyroidism, 132  
   in pituitary tumors, 131  
   treatment of, 134–135  
 metabolism of, 125–135  
   abnormal, 129–135  
 and ovarian cycle, 27  
 receptors in granulosa cells, 42  
 serum levels of, 128–129

Prolapse of pelvic organs, urinary incontinence in, 759–773

Promethazine, in labor, 497

Pronephros, 820, 831

Propranolol  
 effects in pregnancy, 433  
 in hypertension with pregnancy, 637

Prostaglandins  
 affecting myometrium, 140  
 inhibitors of, in management of premature labor, 539  
 and luteolysis, 48, 51  
 and premature labor, 535  
 receptors in granulosa cells, 42  
 synthesis and release of, 140

Prosthetic heart valves, and pregnancy risks, 438–439

Protein  
 in amniotic fluid, 301–302  
 dietary deficiency in pregnancy, 303–305  
 fetal synthesis of, 300–301  
 intake in adolescent pregnancy, 1205–1206  
 serum levels in pregnancy, 299–300  
   341–350  
   relation to infant growth, 305  
 transplacental transmission of, 300

Proteinuria, in pregnancy, 398, 413, 879–880, 938  
 in preeclampsia-eclampsia, 888

Pruritus, vulvar, treatment of, 987, 1102–1104

Psoriasis of vulva, 991–993, 1033, 1035

Psychogenic factors  
 in dyspareunia, 210–212  
 in impotence, 229, 232–233  
 in premature ejaculation, 225–226  
 in urinary incontinence, 701, 709, 745–747, 807–815

Psychological issues, in adolescent pregnancies, 1156–1158, 1162

Psychophysical methods, for pain relief in labor, 495–496

Pubertal development, 67–85, 1137–1140. *See also Adolescence*  
 delayed puberty, 81–84  
   and hypergonadotropic hypogonadism, 81–83  
   and hypogonadotropic hypogonadism, 83–84  
   treatment of, 84  
 and menometrorrhagia, 84–85  
 normal, in females, 67–75  
 in polycystic ovarian disease, 109–112  
 and precocious puberty, 75–81  
   diagnosis of, 79–80  
   heterosexual precocity, 79  
   pseudoprecocious puberty, 78  
   treatment of, 80–81  
   true, 76–78

Pubic hair growth, in puberty, 1140–1142, 1143–1144

Puerperium  
 acute renal failure in, 422  
 uterine infections in, 467–473

Purpura, autoimmune thrombocytopenic, in pregnancy, 391–392

Pyelography, intravenous, in pregnancy, 939

Pyelonephritis, in pregnancy, 424, 870–872, 879, 922

Pyoderma, of vulva, 1000–1002

Radiation dosage, in mammographic screening, 4, 7

Radiation therapy  
 in melanoma, 1126  
 in prolactin-secreting pituitary tumors, 135

Radioisotope renogram, in pregnancy, 941–943

Radiology  
 in fetal maturity evaluation, 549  
 in prenatal diagnosis of fetal disorders, 329–330

Reflux, ureterovesical, in pregnancy, 863–872, 939

Renin production, affected by antihypertensive agents, 645

Renogram, radioisotope, in pregnancy, 941–943

Reproductive cycle, normal, 17–28  
and central nervous system function, 20–24  
feedback mechanisms in, 19–20  
and pituitary function, 24–27

Reserpine, in hypertension with pregnancy, 637

Resuscitation of newborn, 597–602

Rh isoimmunization  
determination in adolescent abortion patients, 1181  
 $\alpha$ -fetoprotein levels in, 345  
and management of newborn, 606  
and ultrasonic diagnosis of fetal ascites, 319–320

Rheumatic heart disease, in pregnancy, 432

Rheumatoid arthritis, in pregnancy, 385–386, 900

Risk assessment, in perinatal medicine, 287–294

Roll-over test, in screening for pregnancy-induced hypertension, 403

Rubella, in pregnancy, 484–485

Rupture of membranes, premature infections in, 462–466  
management of, 539

Sacrospinous ligament fixation, transvaginal, 768–772

Scalp blood analysis, fetal, 582–585  
oxygen values in, 589–590

Scar, atrophic, of vulva, 1032

Schistosomiasis  
intradermal test in, 971  
serologic tests for, 969  
smears in, 971

Sclerosis, progressive systemic, in pregnancy, 389, 419, 900

Screening tests  
for diabetes in pregnancy, 447  
for hypertension in pregnancy, 403  
mammographic, evaluation of, 1–13  
for rubella susceptibility, 485

Sedatives, in preeclampsia–eclampsia, 891–892

Serotonin, and prolactin release, 126

Sex education programs, failures of, 1154–1155

Sex roles, in formerly married persons, 261–262

Sex steroids. *See also* Androgens; Estrogens  
action of, 61–66  
in follicular fluid, 41  
and gonadotropin secretion, 22–23, 57–58  
and pituitary function, 24  
secretion in childhood, 69

Sexism, and gynecologic practice, 173–180

Sexual activity  
patterns in adolescence, 1152–1154, 1161–1162, 1199–1200  
and transmission of vulvar diseases, 959, 1041–1050  
in young women, and counseling programs, 235–248

Sexual maturation, in puberty, 1130–1142

Sexual problems  
and adequate sexual response, 187–188  
in cancer patients, 196  
case histories of, 188–189  
with clitoral hood adhesions, 195  
and communication between partners, 199  
contraceptives affecting, 197–198  
counseling in, 191–202  
and diagnosis and treatment of pathology, 194–197  
drug-induced, 195  
in dyspareunia, 186, 189, 194, 205–217  
environmental factors in, 185, 188  
history-taking in, 183–190  
hormonal factors in, 195  
with hymeneal strand, 196  
impotence, 228–233  
and interference with arousal, 186–187, 188–189  
and lack of knowledge, 186, 189, 192  
male, gynecologic implications of, 223–233  
and mental distractions, 186–187, 189, 193–194  
pain in, 186, 189, 194, 205–217  
in pelvic floor relaxation, 196  
and physical examination as teaching method in, 197  
postmenopausal, 269–277  
case reports of, 270, 271, 274–275  
cultural factors in, 273–274  
estrogen therapy in, 275–277  
and loss of libido, 270  
and pelvic atrophic changes, 274–275  
and premenopausal orgasmic dysfunction, 271–273  
premature ejaculation, 223–228  
prevention of, 201–202  
and role of gynecologist, 191–202  
stimulation evaluation in, 184–185, 188  
in stress incontinence, 195

Sexual problems (*continued*)  
 and vaginal size, 196  
 in vaginismus, 186, 189, 195, 218–220  
 in vaginitis, 194–195, 209

Sheehan's syndrome, anovulation in, 92

Simmonds' disease, anovulation in, 92

Skin, microanatomy of, 1117–1120

Smears, in vulvar diseases, 970–971

Social factors, in adolescent pregnancy, 1152–1153

Social Readjustment Rating Scale, 265–266

Sodium  
 excretion in pregnancy, 857  
 intake in adolescent pregnancy, 1206  
 renal handling of, 848–850  
 restriction in pregnancy, 432  
 retention in preeclampsia-eclampsia, 887–888

Sphingomyelin/lecithin ratio, in amniotic fluid, 553–555  
 in hypertension with pregnancy, 631  
 in infants of diabetics, 450

Spinal cord, and neural control of urethrovesical function, 658–662

Spironolactone, in hypertension with pregnancy, 640

Staphylococcal infections, of vulva, 1000–1002

Stein-Leventhal syndrome. *See* Polycystic ovarian disease

Stents, ureteral, 915

Sterilization, voluntary, in teenagers, 1212

Steroids. *See* Corticosteroids; Sex steroids

Stevens-Johnson syndrome, 1017–1019

Streptococcal infections  
 in pregnancy, 466–467  
 of vulva, 1001–1002

Stress urinary incontinence, 649–815

Surgery  
 cardiovascular, in pregnancy, 433–434  
 cesarean. *See* Cesarean section  
 in condyloma acuminatum, 1072  
 in melanoma, 1125–1126  
 in pituitary tumors, 134–135  
 in urinary incontinence, 764–805  
 failure of, 791–794  
 urologic, in pregnancy, 907–919  
 in vulvar diseases, 973–982

Sympathomimetic drugs, in management of premature labor, 537–538

Symphiotomy, in breech presentation, 516

Syphilis, 1047–1050  
 clinical aspects of, 1048–1049  
 serologic tests in, 968, 1049–1050

Syphilis (*continued*)  
 smears in, 970, 971  
 treatment of, 1050

Tampons, lost, management of, 244–245

Tay-Sachs disease, carriers of, 334

Temperature control, for newborn, 602–603

Testosterone  
 production in normal females, 116–117  
 receptors in granulosa cells, 34–35  
 serum levels of, 74  
 in childhood, 1144

Testosterone-estradiol-binding globulin, 117–118

Testosterone propionate ointment, in lichen sclerosus of vulva, 984–986, 1102

Tetralogy of Fallot, and pregnancy, 436–437

Theca interna, development of, 36

Thelarche, premature, 77–78

Thiazide diuretics, in hypertension with pregnancy, 640

Thrombocytopenic purpura, autoimmune, in pregnancy, 391–392

Thyrotropin-releasing hormone, and prolactin secretion, 126

Tinea, in vulvar area, 996–998

Tocodynamometry, 569

Toluidine blue test, in vulvar disorders, 967, 1104

Toxemia of pregnancy  
 $\alpha$ -fetoprotein levels in, 345  
 and fibrinogen degradation products in serum, 348–350  
 $\beta$ -1-glycoprotein levels in, 346  
 placental lactogen levels in, 366

Transplantation of kidney, pregnancy after, 421, 931–934

Trauma  
 in breech presentations, 523  
 or urinary tract, in pregnancy, 917–918

*Treponema pallidum*, identification of, 970, 971, 1049–1050

Triamcinolone, injections in pruritus of vulva, 1102

Triamterene, in hypertension with pregnancy, 640

Trichloroacetic acid, in condyloma acuminatum, 1070

Trichomonial infections  
 culture specimens in, 970  
 management of, 244  
 smears in, 970

Tuberculosis, renal, in pregnancy, 420, 895–896

Tubular system, renal, 828  
in pregnancy, 413

Tumors  
action of steroid hormones on, 65  
carcinoma of vulva. *See* Vulva  
and evaluation of mammographic screening,  
1–13  
hormonal responsiveness of cells in, 60,  
65–66  
hypothalamic, anovulation in, 94  
melanoma, 1117–1132  
vulvar, 1127–1131

ovarian  
anovulation in, 90–91  
and sex precocity, 78

Paget's disease of vulva, 1107–1114

pelvic, ultrasonic diagnosis in pregnancy,  
326

pituitary  
anovulation in, 92–93  
hyperprolactinemia in, 131

and sexual problems in cancer patients, 196

urinary tract, in pregnancy, 918–919

Turner's syndrome, 89–90

Twin pregnancy. *See* Multiple gestation

Ulcerations, vulvar, 959–960

Ultrasound in obstetrics, 311–326, 330  
with amniocentesis, 322–323, 337–338  
bladder fullness affecting, 323, 338  
fetal studies with, 311–322, 330  
in anencephaly, 315  
in death in utero, 321–322  
and evaluation of maturity, 312, 549  
in fluffy fetus, 320  
in gastrointestinal lesions, 319  
and heart rate monitoring, 566–567  
in hydrocephalus, 315  
identification of anatomic structures,  
313  
location and development, 311–312  
in maternal disease with fetal  
involvement, 319–320  
in meningomyelocele, 317  
in multiple gestation, 314–315  
recognition of anomalies, 315–319  
in renal lesions, 319  
small-for-gestational-age recognition,  
312–313  
in hypertension, 630  
in molar pregnancies, 323–326  
in pelvic masses, 326  
for placental localization, 322–323  
in urologic disorders, 943

Urea therapy, in hypertension with  
pregnancy, 640

Ureter  
anatomy of, 824–825  
duplications of, 836–839  
ectopic orifice of, 754–755  
hormones affecting, 859–860, 866–867  
indwelling stents in, 915  
innervation of, 830  
in pregnancy, 857–861, 907–908  
trauma in pregnancy, 918

Ureteropelvic junction, obstruction in  
pregnancy, 908–910

Ureterovesical reflux, in pregnancy, 863–872,  
939  
and anatomy of vesicoureteral junction,  
863–865  
clinical implications of, 870–872  
cystourethrography in, 870  
physiology of, 865–869

Urethra, 666–667  
anatomy of, 824–825  
diverticula of, 752–753  
electromyography of sphincter, 672–673,  
683–684, 720–721  
embryology of, 823  
pressure studies in incontinence, 713–715  
sphincter activity in urinary incontinence,  
673–678, 685–690  
absence of, 673–674  
with detrusor dyssynergia, 677–678  
dyssynergia of, 675  
with hypotonic bladder, 674–675  
with uninhibited detrusor contraction,  
676–677

Urethritis, 755–756

Urethrocystography, metallic bead-chain,  
725–735, 778, 789–790

Urethrocystoscopy, carbon dioxide, 711, 713,  
737–757

Urethropexy, retropubic, 775–784

Uric acid levels, in pregnancy, 856–857

Urilos monitor, in urinary incontinence,  
721–723

Urinary incontinence, 649–815  
and absence of sphincter activity, 673–674  
from bladder disease, 734  
bladder pressure in, 690–691, 714  
bladder sensation in, 690  
in cystocele, 761  
cystometry in. *See* Cystometry  
in descent of bladder neck, 761–762  
with detrusor dyssynergia and normal  
sphincter, 677–678

Urinary incontinence (*continued*)  
 with detrusor-sphincter dyssynergia,  
 675–676  
 drugs affecting, 747–752  
 and ectopic ureteral orifice, 754–755  
 and electromyography of urethral sphincter,  
 672–673, 683–684, 720–721  
 in estrogen deprivation, 747, 749, 762  
 examination in, 710, 776–778, 788–789  
 and history of patient, 705–710, 776, 788  
 with hypotonic bladder and normal  
 sphincter, 674–675  
 in massive genital prolapse, 762–763  
 metallic bead-chain urothrocystography in,  
 725–735, 778, 789–790  
 and neural control of muscle function,  
 653–667  
 and neurogenic bladder, 701, 743, 744  
 and patterns of detrusor and sphincter  
 activity, 673–678, 685–690,  
 699–701  
 and postural detrusor hyperreflexia, 689–690  
 psychogenic, 701, 709, 745–747, 807–815  
 case reports of, 811–814  
 recurrent, 733, 787–796  
 treatment of, 794–796  
 and sexual problems, 195  
 surgery in, 764–805  
 and correction of perineal defect, 772–773  
 failure of, 791–794  
 partial bladder denervation in, 797–805  
 and restoration of vaginal depth and axis,  
 767  
 retropubic urethropexy in, 775–784  
 sacrospinous ligament fixation in,  
 transvaginal, 768–772  
 selection of procedure in, 731–733  
 with uninhibited detrusor contraction,  
 676–677, 688–690  
 urethral pressure in, 713–715  
 in urethritis, 755–756  
 urethroscopy in, carbon dioxide, 711,  
 713, 737–757  
 urgency component in, 701  
 Urios monitor in, 721–723  
 urinalysis in, 711  
 uroflowmetry in, 711–713, 739, 744  
 videocystourethrography in, 715–720

Urinary tract  
 anatomy of, 819–830  
 calculi in pregnancy, 420, 912–914, 927–928  
 changes in pregnancy, 411–413, 907–908  
 embryology of, 819–824, 831–832  
 infections in pregnancy, 422–424, 870–872,  
 921–928

Urinary tract, infections (*continued*)  
 acute infections, 927  
 diagnostic tests in, 937–944  
 innervation of, 828–830  
 lymphatics of, 830  
 obstructions in pregnancy, 908–912  
 physiology of, 845–852  
 trauma in pregnancy, 917–918  
 tumors in pregnancy, 918–919

Urine  
 concentration of, 847  
 in pregnancy, 939  
 dilution of, 847–848  
 in pregnancy, 939  
 drainage of  
 with indwelling ureteral stents, 915  
 with percutaneous nephrostomy, 915  
 sediment in pregnancy, 937  
 Uroflowmetry, in urinary incontinence,  
 711–713, 739, 744

Urography, in pregnancy, 894–895, 907–908

Uterus  
 bacterial infections in pregnancy, 455–473  
 cervical barrier against bacterial flora, 457  
 molecular biology of contractions in,  
 140–141  
 monitoring of activity in labor, 569–571  
 display with fetal heart rate, 566  
 prostaglandins affecting, 140

Vaccines  
 in condyloma acuminatum, 988, 1063–1064,  
 1072–1076  
 in cytomegalovirus infection, 480  
 in melanoma, 1126–1127  
 in rubella, 485  
 in varicella, 482  
 in Venezuelan equine encephalitis, 484

Vagina  
 discharge from, management of, 243–245  
 self-dilation methods in dyspareunia,  
 215–217  
 size of, and sexual problems, 196

Vaginismus, 186, 189, 195, 218–220  
 definition of, 218–219  
 etiology of, 219–220  
 management of, 220

Vaginitis  
 from rectal intercourse, 244  
 and sexual problems, 194–195, 209

Varicella, in pregnancy, 480–482

Ventilation procedures, for newborn, 597–600

Veratrum alkaloids, in hypertension with  
 pregnancy, 644

Verruca genitalis, 1033, 1035–1036

Videocystourethrography, 715–720  
 Viral infections  
 in pregnancy, 477–486  
 cytomegalovirus, 479–480  
 hepatitis, 482–483  
 herpes, 477–482, 1015–1017  
 rubella, 484–485  
 varicella, 480–482  
 Venezuelan equine encephalitis, 483–484  
 of vulva, 1053–1059  
 condyloma acuminatum, 1061–1076  
 herpes, 1053–1059  
**Vitamin A therapy**, in lichen sclerosis of vulva, 1104  
**Vitamin B<sub>6</sub>**  
 in dysmenorrhea, 141–142, 144  
 in hyperprolactinemia, 135  
**Vitamin requirements**, in adolescent pregnancy, 1207–1208  
**Vitiligo**, of vulva, 1029  
**Vulvar diseases**, 951–1133  
 antimetabolites in, 987–988  
 atrophic disorders, 1032  
 Bartholin's cyst or abscess, 966, 973, 975–977  
 betadine in, 983–984  
 biopsy in, 966  
 blood studies in, 968–969  
 bullous diseases, 1007–1021  
     differential diagnosis of, 1020, 1021  
 candidiasis, 998–999, 1033, 1035  
 carcinoma  
     and condyloma acuminatum, 1065–1066  
     dystrophies related to, 1098–1100  
     5-fluorouracil in, 988  
     and herpesvirus infections, 1058  
         *in situ*, 1033, 1036  
 cellulitis, 1001  
 chancroid, 1046–1047  
 classification of, 955–961  
 condyloma acuminatum, 1061–1076  
 condyloma latum, 1033, 1036  
 contact dermatitis, 1002–1004  
 cryosurgery in, 979–980  
 culture specimens in, 969–970  
 curettage in, 965–966  
 cutaneous, 957–958  
     bullous, 1007–1021  
     infections, 957–958, 996–1002  
     inflammations, 991–996, 1002–1004  
     melanoma, 1127–1131  
 cytologic studies in, 967  
 dermatitis herpetiformis, 1019, 1020  
 diagnosis of, 963–971  
 dye-light therapy in, 984

**Vulvar diseases (continued)**  
 dysplasia, 1087–1090  
 dystrophies, 1025–1029, 1081, 1104  
 hyperplastic, 1028–1029, 1083–1090, 1101  
 mixed, 1028, 1095–1098  
 pathogenesis of, 1098  
 relation to cancer, 1098–1100  
 symptoms of, 1100–1101  
 treatment of, 1101–1104  
 ecthyma, 1001  
 electrosurgery in, 977–978  
 with erosions or ulcerations, 959–960  
 erysipelas, 1001  
 erythema multiforme, 1017–1019, 1020  
 erythrasma, 999–1000  
 examination in, 964–965  
 excision of lesions in, 966, 973–975  
 fluorescence studies with Wood's light, 968  
 folliculitis, 1001  
 gentian violet in, 973, 983  
 granuloma inguinale, 1041–1043  
 herpesvirus infections, 1053–1059  
     gestationis, 1015–1017  
 histologic examination in, 965–966  
 history-taking in, 957–964  
 hormone therapy in, 984–987  
 hypertrophic disorders, 1033–1037  
 immunofluorescence studies in bullous disease, 966–967  
 immunotherapy in, 988  
 impetigo, 1001  
 intertrigo, 1033  
 laser therapy in, 980–982  
 lichen planus, 993–994, 1029  
 lichen sclerosus, 1025–1028, 1090–1095  
     in childhood, 1104  
     treatment of, 1101–1102  
 lichen simplex chronicus, 995–996, 1033, 1035, 1083  
 lymphogranuloma venereum, 1043–1046  
 marsupialization in Bartholin cysts, 966, 975–977  
 medical treatment in, 982–988  
 melanoma, 1127–1131  
 neurodermatitis, 995–996  
 Paget's disease, 1107–1114  
 patch testing in, 968, 1003  
 pemphigoid  
     benign mucous membrane, 1014–1015, 1020  
     bullous, 1013–1014, 1020  
 pemphigus, 1007–1013, 1020  
     familial benign chronic, 1011–1013  
 pruritus in, treatment of, 987, 1102–1104  
 psoriasis, 991–993, 1033, 1035

Vulvar diseases (*continued*)  
  pyodermas, 1000–1002  
  seborrheic dermatitis, 994  
  sexually transmitted diseases, 959,  
    1041–1050  
  smears in, 970–971  
  surgery in, 973–982  
  syphilis, 1047–1050  
  tinea, 996–998  
  toluidine blue test in, 967, 1104  
  treatment of, 973–989  
  undetermined disorders, 959  
  verruca genitalis, 1033, 1035–1036  
  viral infections, 1053–1059  
    condyloma acuminatum, 1061–1076  
    herpesvirus, 1053–1059  
vitiligo, 1029  
vulvovaginal, 958  
white lesions in, 960, 1023–1038, 1081  
  invariably white, 1025–1031  
  potentially white, 1025, 1032–1037

Vulvovaginitis, 958

Warts, genital, 1033, 1035–1036. *See also*  
  Condyloma

Water retention, in preeclampsia-eclampsia, 887

Weight  
  at birth. *See* Birth weight  
  gain in pregnancy, 413  
  in adolescence, 1205  
  affecting infant, 305  
  in preeclampsia-eclampsia, 887  
  gain in puberty, 1139–1140

White lesions of vulva, 960, 1023–1038, 1081

Wickham's striae, in lichen planus, 993

Widows, counseling of, 259–266

Women  
  counseling of. *See* Counseling  
  health care for, attitudes in, 173–180  
  normal female development, 67–75

Wood's light fluorescence studies, in vulvar disease, 968

Word catheter, in Bartholin abscesses, 973, 977

Zatuchni-Andros scoring system, in breech presentations, 526

Zinc  
  deficiency in pregnancy, 308  
  intake in adolescent pregnancy, 1207

